1. Introduction {#s0005}
===============

Length of stay (LOS) is defined as the number of bed days in each inpatient episode ([@b0005]). It has been identified to be one of the main indicators of hospital performance and patients' consumption of resources ([@b0005], [@b0010], [@b0015]). In Singapore, the mean LOS in the public acute care hospitals is 5.8 days in 2012 ([@b0020]). Based on the 2012 data, most patients were admitted into the hospital due to accident, poisoning and violence (8.3%), cancer (6.0%) or ischemic heart disease (3.6%) [@b0025]. The national healthcare expenditure constitutes about 4% of Singapore Gross Domestic Product (GDP) in 2013 and is projected to increase as the population ages ([@b0295]).

In 2011, healthcare expenditures constituted about 18 percent of the Gross Domestic Product (GDP) in the United States ([@b0035]). As an important variable contributing to cost, increased LOS exerts substantial financial burden on the healthcare system. Extensive studies have also found that reduction in LOS is associated with cost savings. National Health Service (NHS) Institute for Innovation and Improvement in the United Kingdom projected an annual saving of approximately £8 million if the average LOS was shortened by one day ([@b0040]). A study conducted in the United States also showed that with a 1-day and 2-day reduction in LOS, the estimated cost savings could amount to \$680 and \$1408 respectively ([@b0045]). Reducing LOS will increase the capacity such as inpatient beds and manpower in the healthcare system, improving its productivity and efficiency ([@b0040]). Besides, with an increase in LOS, unplanned rehospitalization and a rise in the adverse drug reactions of all severities could be resulted ([@b0050], [@b0055]). A 6.1% probability of adverse drug reactions, 20.6% probability of infections and 2.5% probability of ulcers were correlated with a LOS of 8 days 7 nights ([@b0060]). As patients' LOS increase, patients are exposed to a greater risk of an adverse event ([@b0060]). LOS therefore, has notable implications on patients' health and the usage of healthcare resources.

While physician and hospital affect LOS, patient characteristics and their medications prior to hospitalization play significant roles in influencing LOS as well ([@b0005], [@b0065], [@b0070]). A study on the medication use in Singapore nursing homes found that on average, the residents were on 5.32 medications ([@b0075]). Patients' extended LOS due to drug related causes are often preventable and their drug related problems (DRPs) can be attributed to polypharmacy ([@b0080], [@b0085]). Non-compliance, a commonly cited DRP can be ameliorated through the reduction of pill burden and simplification of regimens ([@b0085]). Although the reduction of pill burden could potentially improve patients' disease control and thereby lead to a reduction in LOS, no direct association has been clearly shown between such an intervention and LOS. Furthermore, previous studies had presented varied responses on the relationship of polypharmacy and LOS ([@b0090], [@b0095], [@b0100]). Studies conducted by Campbell et al. and Incalzi et al. showed that polypharmacy is significantly related to extended LOS ([@b0095], [@b0100]). On the other hand, Nobili et al. suggested otherwise as polypharmacy was found to be unrelated to LOS in their study ([@b0090]).

2. Aim of the study {#s0010}
===================

Our study aimed to explore the association between patients' pill burden, more specifically in terms of Total Daily Doses (TDD) and their LOS upon readmission. We hypothesized that higher TDD is associated with longer patient's LOS, potentially due to non-compliance.

3. Methods {#s0015}
==========

3.1. Study design {#s0020}
-----------------

A retrospective, cross-sectional study was conducted at a regional hospital in Singapore. This study was performed using the electronic medical databases shared by healthcare institutions across Singapore.

Institutional board review and waiver of patients' written informed consent were obtained from the National Healthcare Group, Singapore.

3.2. Subjects {#s0025}
-------------

Patients aged above 18 who were first admitted to the regional hospital and subsequently readmitted to any healthcare institutions in Singapore between 1st January and 31st March 2013 were included in this study. Readmission was defined as any unscheduled admission within 15 days of any discharge during the study period.

Patients' baseline demographic characteristics and clinical data were examined through the review of medical records. Demographic data collected were age, gender, race. Patients' race was categorized based on the 3 major ethnic groups in Singapore, namely Chinese, Malay, and Indians. Patients who were not placed into one of these 3 categories were classified as "others". This categorization was important as different ethnic groups had shown significant differences in their health status for the same medical condition ([@b0105]). The classification of comorbidities was taken from Charlson Comorbidity Index (CCI) [@b0110].

LOS was defined as the number of days from the first day readmission till the day of discharge. It was numbered sequentially and counted with day 1 being the day of readmission. For example, if the patient was readmitted into the hospital on 10th March 2013 and was discharged on 12th March 2013, the LOS was taken as 3 days.

The number of medications and TDD in this study was defined as the maximum number of medications and doses a patient takes a day. This consisted of acute, chronic, prescription, non-prescription medications, supplements, and those medications that were to be taken when is needed, irrespective of their dosage forms. Medications containing the same active pharmaceutical ingredient but of different dosage forms were considered to be different medications. For example, betamethasone cream and ointment applied by the same patient would be counted as two distinct medications. Different strengths of same medication that had the same dosing frequency on different days were regarded as one medication. Some patients took warfarin 5 mg tablets on certain days of the week and warfarin 3 mg tablets for the remaining days. Warfarin 5 mg and 3 mg tablets here were then counted as one medication only. At the same time, medications such as Alendronate that were taken once weekly were counted as one dose.

The number of medications and TDD was obtained from patients' previous hospital discharge summary. If no medications had been provided in the previous discharge, the number of chronic medications that was dispensed on the nearest date before the previous discharge was taken into account instead.

Patients' DRPs documented in the discharge summary were included in this study. This documentation was done by the clinicians on a voluntary basis and it was based on their clinical judgment. The DRP classification in this was study was adapted from the definitions of [@b0115]. They were further broken down into smaller classifications included hypoglycemia, hyponatremia, constipation, on top of other DRPs such as over dosage and subtherapeutic dosage.

3.3. Analysis {#s0030}
-------------

STATA SE version 12.1 for Windows (Stata Corp, College Station, TX) was used in all the statistical analyses.

Descriptive statistics were used to show patient characteristics in the readmission cases collected. Characteristics such as patients' demographics, types of comorbidities, LOS were expressed as mean ± standard deviation or number (percentage).

Univariable linear regression was performed using number of medications, TDD, demographics, types and number of comorbidities and types of DRPs as the independent variables and LOS as the dependent variable. All the variables, irrespective of their *p*-values and significance, were included in this analysis in order to attain a complete picture of the relationships of LOS with other variables. Earlier studies suggested that patients aged \>75 years were associated with greater risk of hospital readmission and their readmissions were attributed to adverse drug events, hence the age was fixed at 75 year-old in univariable linear regression to examine its association with LOS ([@b0120], [@b0125]).

Statistical significance was defined as *p* \< 0.05. Independent variables that exhibited significant relationships in the univariable regression were included in the multivariable linear regression. Multivariable linear regression was performed using LOS as the dependent variable. The number of medications and TDD was used as the independent variables in separate models. The multivariable linear regressions were adjusted with comorbidities and DRPs as they could be confounding factors to the analysis. In this model, being a male, being a Chinese, absence of comorbidities and absence of DRP were the reference categories for gender, race, types of comorbidities and types of DRPs respectively.

To avoid multicollinearity, care was taken to ensure that the variance inflation factor (VIF) to be less than 1 in the analysis.

4. Results {#s0035}
==========

Overall, 432 patients met the eligibility criteria and 649 readmissions were evaluated for this study.

4.1. Baseline characteristics of patients {#s0040}
-----------------------------------------

In the 649 readmission cases collected, patients were aged 67.7 ± 16.2 year-old. Majority of the patients were Chinese (60%, *n* = 388), followed by Malay (19%, *n* = 122) and Indian (13%, *n* = 85). The number of male (52%, *n* = 339) and female (48%, *n* = 310) patients was comparable. Meanwhile, patients involved in readmission had an average of 3.33 ± 1.91 comorbidities. Hypertension, dyslipidemia and diabetes were the main comorbidities, comprising 63% (*n* = 411), 51% (*n* = 331) and 46% (*n* = 299) respectively of the total number of readmissions.

LOS ranged from 1 to 90 days and the mean LOS was 7.63 days ± 7.08. Most of the readmission had a LOS of 2--4 days, making up 36% (*n* = 233) of the total number of readmission events.

On average, the TDD was 18.0 ± 8.2 while the number of medications was 10.0 ± 4.4. The main DRP encountered in this study was non-compliance (6%, *n* = 36). [Table 1](#t0005){ref-type="table"} showed the summary of the characteristics of readmission events included in the analysis.

4.2. Statistical modeling {#s0055}
-------------------------

In the univariable analysis as shown in [Table 2](#t0010){ref-type="table"}, a significant relationship (*p* \< 0.05) was established between LOS during readmission and variables of age (more than 75 year-old), race, comorbidity (hypertension, dyslipidemia, CKD, depression), number of comorbidities, number of medications, TDD and thrombocytopenia as a DRP.

In [Table 3](#t0015){ref-type="table"}, the multiple linear regression that was adjusted with comorbidities and DRP revealed a statistically significant relationship between TDD (*β* = 0.073, *p* = 0.030) and LOS. The variables that reached significance included age more than 75 year-old (*β* = 1.547, *p* = 0.008), Malay (*β* = −1.512, *p* = 0.033), race of others (*β* = −2.617, *p* = 0.007), depression as a comorbidity (*β* = 2.155, *p* = 0.031) and thrombocytopenia as a type of DRP (*β* = 7.554, *p* = 0.027). When TDD was substituted by the number of medications, the same variables remained significant, namely, number of medications (*β* = 0.148, *p* = 0.021), age more than 75 year-old (*β* = 1.530, *p* = 0.009), Malay (*β* = −1.468, *p* = 0.038), race of others (*β* = −2.6499, *p* = 0.007), depression as a comorbidity (*β* = 2.195, *p* = 0.028) and thrombocytopenia as a type of DRP (*β* = 7.5260, *p* = 0.028).

5. Discussion {#s0045}
=============

This study identified that TDD was significantly associated with LOS in both univariable (*β* = 0.116, *p* = 0.001) and multiple linear regression (*β* = 0.073, *p* = 0.030). Earlier studies found that the number of medications was unassociated with LOS ([@b0090], [@b0130]). However, our results suggested otherwise in both univariable (*β* = 0.241, *p* \< 0.001) and multiple linear regression (*β* = 0.148, *p* = 0.021) as polypharmacy contributed substantially to patients' LOS upon their readmission. This difference may be because we included both prescription and over-the-counter (OTC) medications in our study while earlier studies only took prescription medications into consideration. As the exclusion of OTC medications was suspected to cause the underestimation of the total number of medications taken by the population in other studies, OTC medications were counted to better reflect the actual pill burden of the patients ([@b0135]). In addition to the potential adverse consequences such as DRPs and unintended hospital admissions attributed to OTC medications, there is a high prevalence of concurrent use of both prescription and OTC medications ([@b0140], [@b0145]). Hence, it was essential to estimate their effects on LOS. This study provided significant insights into the association between pill burden and LOS. To date, the majority of studies on LOS focus on polypharmacy and DRPs, this study was the first to associate the LOS with TDD as well as the number of medications ([@b0090], [@b0145], [@b0150]). On top of other implications caused by polypharmacy, this finding would prompt clinicians to use the least possible number of TDDs and medications ([@b0155], [@b0160]).

In this study, patients' LOS could be attributed to DRPs caused by high TDD. Due to the nature of a retrospective study, there may be an underestimation of DRPs, causing most of the DRPs to be non-significantly related to LOS. However, as earlier studies had demonstrated that DRPs increase patients' LOS in the hospital, DRPs could still be a plausible link for this association between TDD and LOS in this study ([@b0165], [@b0170]).

The multiple linear regressions for the total number of readmissions revealed racial category of Malay and others (encompassed Eurasians, Sinhalese and other minority races) to be significantly associated with LOS. Consistent with the findings from other studies, racial disparity was common in other populations and this had been highlighted ([@b0175], [@b0180], [@b0185]). In a European study, researchers found that non-Western ethnic groups had a higher risk for increased LOS as compared to ethnic Dutch patients ([@b0185]). Therefore, clinicians may have to take ethnicity into consideration when examining patients' health outcomes and estimating their LOS.

As mentioned by Uldall et al., there is a significant correlation between psychological comorbidity and LOS ([@b0190]). In the present study, depression as a comorbidity had a significant relationship with LOS and this was shown in both univariable and multiple linear regressions. This correlation was confirmed by prior studies where psychiatric comorbidity increased patients' average LOS ([@b0190], [@b0195], [@b0200]). Thus, clinicians who are attending to psychiatric patients should be prepared for the possibility of prolonged LOS.

LOS was associated to having thrombocytopenia as a DRP in both univariable and multiple linear regressions. Literatures from the United States and Canada had also documented that patients suffering from thrombocytopenia could have long LOS in the hospital or more specifically the specialized units ([@b0205], [@b0210]). This finding would caution clinicians of the increased risk of prolonged LOS if their patients have DRPs, in particular thrombocytopenia.

5.1. Limitations {#s0050}
----------------

Similar to other retrospective studies where important data may not be available, there was an absence of the severity of comorbidities in this study ([@b0215]). Comorbidities such as hypertension and diabetes that were shown to be associated with patients' LOS in earlier study did not demonstrate significant association ([@b0220]). Only depression as comorbidity was significantly associated to LOS. Therefore, this study failed to confirm the statistical significance between comorbidities and LOS that were detected by other studies at the multiple linear regression level ([@b0225]). Similarly, while the complexity and severity of the patients' conditions upon admission were recognized to be a major determining factor of LOS, this information could be not be clearly accounted for in this study ([@b0005]). Notably, this was a common issue seen in risk prediction models for hospital readmissions as limited studies evaluated illness severity ([@b0230]).

Besides, the definitions of the different types of DRPs were not standardized. The difference in the definitions of DRPs such as non-compliance could lead to variations in the study outcomes ([@b0235]). Without standardized definitions of DRPs, clinicians could have failed to record the possible DRPs. This could potentially lead to an underestimation of the cases related to DRP.

The LOS in this study was taken from the readmissions within 15 days of discharge, while many other studies adopted 30-day readmission ([@b0230]). Hence, fewer events were included in this study as compared to other studies on LOS ([@b0090], [@b0240]). While Fine et al's study on LOS numbered it by representing the day of admission as day 0, this study numbered the day of admission as day 1 ([@b0045]). As such, the definition of LOS was either unclear or absent in a number of studies on LOS ([@b0090], [@b0095], [@b0100], [@b0165], [@b0225]). Although this deviation and ambiguity in the definition may potentially introduce discrepancies in the results, this difference was assumed to be negligible till other studies prove otherwise.

5.2. Implications {#s0060}
-----------------

This is the first study to use TDD to investigate the effect of patients' pill burden on their LOS and to establish significant association between TDD and LOS. As far as we know, there had been scant information on the association between number of medications and LOS and there had been no significant associations found ([@b0090], [@b0130]). This study however yielded a significant relationship between numbers of medications and LOS when all the medications (prescription, non-prescription, chronic, acute) were included. Hence, this study introduced a new dimension to the current studies on LOS and polypharmacy as pill burden in terms of TDD was taken into account. TDD is a legitimate concern and important variable to look into. As dosing frequency is known to be one of the main barriers to adherence, less frequent dosing is encouraged ([@b0245], [@b0250], [@b0255]). This finding would motivate clinicians to take TDD into serious considerations when they prescribe or carry out medical reconciliation.

TDD reduction could be achieved through the use of extended release formulation or combination drugs. This had been reported to minimize patients' risk of taking duplicate medications, enhance their symptomatic control for certain disease states as well as to improve their compliance ([@b0260], [@b0265], [@b0270]). TDD reduction and better compliance could translate into reduced healthcare resource utilization and costs ([@b0260], [@b0275]). However, TDD reduction also presented potential disadvantages. Though these modified products reduce TDD, they were associated with delayed achievement of pharmacodynamics effect and sustained toxicity ([@b0280], [@b0285]). At the same dosing, the effectiveness of the treatment could be compromised when TDD is reduced. Malo et al. reported that administering budesonide on a four times daily basis instead of twice daily was more effective in controlling asthma, although patients were less compliant and were exposed to more adverse effects ([@b0290]). Certain medications may also be inappropriate for reduced dosing frequency because possible adverse events could be culminated from their pharmacokinetic and pharmacodynamics ([@b0260]).

Future prospective studies are warranted to examine the significance of TDD reduction based interventions on the improvement of patients' LOS. In view of the implications of polypharmacy, it was initially hypothesized in this study that DRP was the cause of the significant relationship between TDD and LOS ([@b0165], [@b0170]). Although this study did not show that DRP was the link in the association between TDD and LOS, this introduced a room for future prospective studies with standardized definition of DRPs to confirm this hypothesis.

6. Conclusion {#s0065}
=============

We conclude that TDD before patient's readmission had a significant association with patients' LOS upon readmission. Medication regimen simplification through approaches such as the use the extended release products could be considered to minimize patients' DRP and their LOS.

Peer review under responsibility of King Saud University.

###### 

Characteristics of events.

  Feature                    Total number of events (*N* = 649)
  -------------------------- ------------------------------------
  Age (years)                67.7 ± 16.2
                             
  *Race*                     
  Chinese                    388 (60)
  Malay                      122 (19)
  Indian                     85 (13)
  Others                     54 (8)
                             
  *Gender*                   
  Male                       339 (52)
  Female                     310 (48)
                             
  Total daily dose           18.0 ± 8.2
  Number of medications      10.0 ± 4.4
  Number of co-morbidities   3.3 ± 1.9
                             
  *Types of co-morbidites*   
  Diabetes                   299 (46)
  Hypertension               411 (63)
  Dyslipidemia               331 (51)
  CHD                        213 (33)
  COPD                       41 (6)
  Epilepsy                   29 (4)
  Asthma                     63 (10)
  CVA                        87 (13)
  CHF                        33 (5)
  Liver disease              50 (8)
  CKD                        79 (12)
  Osteoarthritis             40 (6)
  Osteoporosis               19 (3)
  Gout                       45 (7)
  Cataract                   39 (6)
  Dementia                   50 (8)
  Alzheimer's                9 (1)
  Depression                 53 (8)
  Anemia                     148 (23)
  Cancer                     62 (10)
  BPH                        41 (6)
  Thyroid                    33 (5)
  Schizophrenia              30 (5)
  Hemorrhoid                 2 (1)
  Hemiplegia                 7 (1)
  Ulcer disease              40 (6)
  PKD                        19 (3)
                             
  *DRPs*                     
  Non-compliance             36 (6)
  Hypoglycemia               6 (1)
  Hyponatremia               4 (1)
  Hypokalemia                4 (1)
  Metabolic alkalosis        1 (1)
  Dehydration                6 (1)
  Low blood pressure         4 (1)
  LFT abnormalities          5 (1)
  Supratherapeutic dose      10 (2)
  Subtherapeutic dose        1 (1)
  Rashes                     4 (1)
  Anemia                     2 (1)
  Thrombocytopenia           4 (1)
  N/V/D                      4 (1)
  Drowsiness/giddiness       5 (1)
  Constipation               1 (1)
  Length of stay (LOS)       7.63 ± 7.08
  1                          19 (3)
  2                          70 (11)
  3                          76 (12)
  4                          87 (13)
  5                          61 (9)
  6                          57 (9)
  7                          46 (7)
  8                          42 (7)
  9                          37 (6)
  10                         24 (4)
  11                         13 (2)
  12                         20 (3)
  13                         15 (2)
  14                         13 (2)
  15--19                     33 (5)
  20--24                     18 (3)
  25--30                     13 (2)
  36--90                     5 (1)

Data shown as mean ± SD or *n* (%).

*Abbreviations:* Coronary heart disease (CHD), chronic obstructive pulmonary disease (COPD), cerebrovascular disease (CVD) benign prostatic hyperplasia (BPH), Parkinson's disease (PKD), liver function test (LFT), nausea, vomiting, diarrhea (N/V/D), drug-related problem (DRP).

###### 

Univariable regression with duration of readmissions and variables.

                                                       Duration of readmissions                       
  ---------------------------------------------------- -------------------------- ------------------- ---------
  Total daily dose                                     11.65                      5.01, 18.29         0.001
  Number of medications                                24.14                      11.96, 36.33        \<0.001
  Age (more than 75 year-old)                          206.02                     94.63, 317.41       \<0.001
                                                                                                      
  *Race*[a](#tblfn1){ref-type="table-fn"}                                                             
  If Malay                                             −215.53                    −358.48, −72.57     0.003
  If Indian                                            −175.48                    −340.42, −10.54     0.037
  If others                                            −285.96                    −486.00, −85.92     0.005
                                                                                                      
  *Gender*[b](#tblfn2){ref-type="table-fn"}                                                           
  If female                                            150.2                      −41.44, 258.95      0.007
                                                                                                      
  *Co-morbidities*[c](#tblfn20){ref-type="table-fn"}                                                  
  Diabetes                                             −21.59                     −131.18, 88.00      0.699
  Hypertension                                         193.13                     80.75, 305.51       0.001
  Dyslipidemia                                         110.91                     1.95, 219.86        0.046
  CHD                                                  20.11                      −96.23, 136.46      0.734
  CVA                                                  158.98                     −0.90, 318.86       0.051
  CHF                                                  220.45                     −27.65, 468.56      0.081
  COPD                                                 137.91                     −86.41, 362.23      0.228
  Asthma                                               −159.96                    −344.09, 24.16      0.088
  Liver disease                                        −129.46                    −334.09, 75.18      0.215
  CKD                                                  203                        36.65, 369.35       0.017
  Osteoarthritis                                       −67.65                     −294.77, 159.47     0.559
  Osteoporosis                                         −22.02                     −346.10, 302.06     0.894
  Gout                                                 115.65                     −99.24, 330.53      0.291
  Cataract                                             30.67                      −199.20, 260.54     0.793
  Anemia                                               46.43                      −83.73, 176.59      0.484
  Cancer                                               154.5                      −30.97, 339.98      1.64
  BPH                                                  20.76                      −203.81, 245.32     0.856
  Thyroid disease                                      102.33                     −146.24, 350.89     0.419
  Hem                                                  638.49                     −345.96, 1622.93    0.203
  Epilepsy                                             −149.47                    −413.65, 114.70     0.267
  Dementia                                             171.75                     −32.70, 376.20      0.1
  Depression                                           282.21                     83.90, 480.51       0.005
  Alzheimer's disease                                  −154.51                    −621.55, 312.52     0.516
  Schizophrenia                                        66.25                      −193.90, 326.39     0.617
  PKD                                                  173.17                     −150.64, 496.97     0.294
  Hemiplegia                                           8.03                       −520.88, 5.36.95    0.976
  Ulcer disease                                        −57.00                     −284.13, 170.14     0.622
  Number of comorbidities                              42.50                      14.11, 70.88        0.003
                                                                                                      
  *Types of DRP*[d](#tblfn3){ref-type="table-fn"}                                                     
  Non-compliance                                       138.65                     −99.79, 377.10      0.254
  Hypoglycemia                                         −350.05                    −920.26, 220.16     0.228
  Hyponatremia                                         −231.63                    −1037.40, 574.14    0.573
  Hypokalemia                                          −13.57                     −1000.71, 973.58    0.978
  Metabolic alkalosis                                  −163.73                    −1556.56, 1229.09   0.818
  Dehydration                                          322.84                     −247.47, 893.14     0.267
  Low blood pressure                                   −265.12                    −962.88, 432.64     0.456
  Giddiness                                            36.8                       −588.04, 661.64     0.908
  LFT abnormalities                                    38.51                      −658.70, 735.71     0.914
  N/V/D                                                112.21                     −585.80, 810.22     0.752
  Constipation                                         236.88                     −1155.88, 1629.65   0.739
  Anemia                                               638.49                     −345.96, 1622.93    0.203
  Thrombocytopenia                                     841.71                     146.68, 1536.74     0.018
  Rashes                                               −214.81                    −912.67, 483.06     0.546
  Supratherapeutic dose                                296.48                     −257.12, 850.08     0.293
  Subtherapeutic dose                                  437.19                     −955.29, 1829.67    0.538

*Abbreviations:* Coronary heart disease (CHD), chronic obstructive pulmonary disease (COPD), cerebrovascular disease (CVD) benign prostatic hyperplasia (BPH), Parkinson's disease (PKD), liver function test (LFT), nausea, vomiting, diarrhea (N/V/D), not significant (NS); *p* \> 0.05, drug-related problem (DRP).

Chinese as reference group.

Male as reference group.

Absence of comorbidities as reference group.

Absence of DRP as reference group.

###### 

Multiple linear regressions with duration of readmissions and total daily dose or number of medications after adjustments with covariates.

                                                      Duration of readmissions                                                         
  --------------------------------------------------- -------------------------- ----------------- ------- --------- ----------------- -------
  Total daily dose                                    7.33                       0.71, 13.94       0.03    NA        NA                NA
  Number of medications                               NA                         NA                NA      14.87     2.26, 27.47       0.021
  Age (more than 75 year-old)                         154.77                     40.43, 269.11     0.008   153.03    38.67, 267.40     0.009
                                                                                                                                       
  *Race*[a](#tblfn4){ref-type="table-fn"}                                                                                              
  If Malay                                            −151.23                    −290.32, −12.13   0.033   −146.87   −285.75, −7.98    0.038
  If Indian                                           −104.62                    −270.23, 61.00    0.215   −106.48   −272.02, 59.06    0.207
  If others                                           −261.74                    −452.73, −70.74   0.007   −264.99   −455.96, −74.02   0.007
                                                                                                                                       
  *Gender*[b](#tblfn5){ref-type="table-fn"}                                                                                            
  If female                                           91.54                      −14.71, 197.78    0.091   89.68     −16.58, 195.94    0.098
                                                                                                                                       
  *Co-morbidities*[c](#tblfn6){ref-type="table-fn"}                                                                                    
  HTN                                                 95.15                      −27.62, 217.93    0.129   82.5      −41.62, 206.62    0.192
  HLD                                                 13.25                      −102.44, 128.94   0.822   6.6       −109.57, 122.76   0.911
  CKD                                                 161.29                     −0.72, 323.30     0.051   157.08    −5.19, 319.35     0.058
  Depression                                          215.51                     19.90, 411.12     0.031   219.51    24.16, 414.86     0.028
                                                                                                                                       
  *Types of DRP*[d](#tblfn7){ref-type="table-fn"}                                                                                      
  Supratherapeutic dose                               292.26                     −246.23, 830.74   0.287   268.88    −270.31, 808.07   0.328
  Thrombocytopenia                                    755.48                     84.25, 1426.71    0.027   752.6     81.70, 1423.51    0.028

*Abbreviations:* Drug-related problem (DRP).

Chinese as reference group.

Male as reference group.

Absence of comorbidities as reference group.

Absence of DRP as reference group.
